These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 15463852)
1. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics. Pirzada OM; McGaw J; Taylor CJ; Everard ML J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852 [TBL] [Abstract][Full Text] [Related]
2. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698 [TBL] [Abstract][Full Text] [Related]
3. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. Hansen CR; Pressler T; Koch C; Høiby N J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679 [TBL] [Abstract][Full Text] [Related]
4. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. Hansen CR; Pressler T; Hoiby N; Johansen HK J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202 [TBL] [Abstract][Full Text] [Related]
6. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694 [TBL] [Abstract][Full Text] [Related]
7. Azithromycin for improving pulmonary function in cystic fibrosis. Carr RR; Nahata MC Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312 [TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC; Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785 [TBL] [Abstract][Full Text] [Related]
9. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350 [TBL] [Abstract][Full Text] [Related]
10. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. Phaff SJ; Tiddens HA; Verbrugh HA; Ott A J Antimicrob Chemother; 2006 Apr; 57(4):741-6. PubMed ID: 16469851 [TBL] [Abstract][Full Text] [Related]
11. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Stelmach I; Korzeniewska A; Stelmach W Respiration; 2008; 75(2):178-81. PubMed ID: 17435382 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. Jarad NA; Giles K Chron Respir Dis; 2008; 5(1):29-33. PubMed ID: 18303099 [TBL] [Abstract][Full Text] [Related]
13. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum. Baxter CG; Rautemaa R; Jones AM; Webb AK; Bull M; Mahenthiralingam E; Denning DW Thorax; 2013 Jul; 68(7):652-7. PubMed ID: 23513028 [TBL] [Abstract][Full Text] [Related]
14. Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. Esmond G; Butler M; McCormack AM J Clin Nurs; 2006 Jan; 15(1):52-60. PubMed ID: 16390524 [TBL] [Abstract][Full Text] [Related]
15. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Nguyen D; Emond MJ; Mayer-Hamblett N; Saiman L; Marshall BC; Burns JL Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154 [TBL] [Abstract][Full Text] [Related]
16. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. Shitrit D; Bendayan D; Gidon S; Saute M; Bakal I; Kramer MR J Heart Lung Transplant; 2005 Sep; 24(9):1440-3. PubMed ID: 16143268 [TBL] [Abstract][Full Text] [Related]
17. [Antibiotic therapy and effects of respiratory physiotherapy techniques in cystic fibrosis patients treated for acute lung exacerbations: an experimental study]. da Silva Santos CI; Gonçalves de Oliveira Ribeiro MA; Moreno Morcillo A; Fernando Ribeiro A; Dirceu Ribeiro J Arch Bronconeumol; 2010 Jun; 46(6):310-6. PubMed ID: 20417019 [TBL] [Abstract][Full Text] [Related]
18. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. McPhail GL; Acton JD; Fenchel MC; Amin RS; Seid M J Pediatr; 2008 Dec; 153(6):752-7. PubMed ID: 18760423 [TBL] [Abstract][Full Text] [Related]
19. Improved pulmonary and growth outcomes in cystic fibrosis by newborn screening. Collins MS; Abbott MA; Wakefield DB; Lapin CD; Drapeau G; Hopfer SM; Greenstein RM; Cloutier MM Pediatr Pulmonol; 2008 Jul; 43(7):648-55. PubMed ID: 18500732 [TBL] [Abstract][Full Text] [Related]
20. Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis. Nazer D; Abdulhamid I; Thomas R; Pendleton S Pediatr Pulmonol; 2006 Aug; 41(8):744-9. PubMed ID: 16779852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]